| | Cell line | Cell type/animal models | Specific results | Mode of action | References |
| | H1650 and H1975 | Non-small cell lung cancer | Evodiamine (0, 2, 4, 8, 16 μM; 24 h) suppressed IFN-γ-induced PD-L1 expression in H1975 and H1650 cells. MUC1-C mRNA and protein expression were decreased by evodiamine (0, 2, 4, 8, 16 μM; 24 h) in NSCLC cells as well. Evodiamine (0, 2, 4, 8, 16 μM; 24 h) downregulated the PD-L1 expression and diminished the apoptosis of T cells. It inhibited MUC1-C expression and potentiated CD8+ T-cell effector function. | Elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 signaling pathway | [94] | | A549, H460, H1299, and H1650 | Non-small cell lung cancer | The cells were treated with evodiamine (3 μM), erlotinib (20 μM), or the combination for 48 h. Combining evodiamine with erlotinib successfully inhibited cell proliferation and survival in wild-type EGFR NSCLC cells, characterized as erlotinib-resistant. In addition, evodiamine plus erlotinib significantly increased the apoptotic rate (61.86%) of NSCLC cells, as compared to single-agent treatment alone (evodiamine ∼33.71%; erlotinib ∼21.92%). | mTOR/S6K1- mediated downregulation of Mcl-1 | [95] | | Caco-2 and HT-29 | Colorectal adenocarcinoma | Evodiamine (10 μM) enhanced the effect of berberine (0, 2.5, 5, 10, 20, 40 μM) on cell viability with IC50 values ranging from 38.85 μM to 15.82 μM in Caco-2 cells at 24 h, but evodiamine did not have this effect in HT-29 cells. | Attenuating the overexpression of P-gp gene | [96] |
|
|
